Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4941)
All Articles published online
|
Publishing Process of This Article
|
Jul 27, 2013 (publication date) through May 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371 [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v5/i7/364.htm |
| Number | Citing Articles |
| 1 |
Giovan Giuseppe Di Costanzo, Raffaella Tortora. Intermediate hepatocellular carcinoma: How to choose the best treatment modality?. World Journal of Hepatology 2015; 7(9): 1184-1191 doi: 10.4254/wjh.v7.i9.1184
|
| 2 |
Wei-Ting Chen, Shi-Ming Lin, Wei-Chen Lee, Ting-Jung Wu, Chen-Chun Lin, Chien-Heng Shen, Ming-Ling Chang, Chih-Lang Lin, Chau-Ting Yeh. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatology International 2022; 16(1): 148 doi: 10.1007/s12072-021-10283-7
|
| 3 |
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi, Andrea Lorenzo Inghilesi. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World Journal of Hepatology 2015; 7(8): 1041-1053 doi: 10.4254/wjh.v7.i8.1041
|
| 4 |
Yuanjian Huang, Xiang Cheng, Ping Sun, Tong Li, Zifang Song, Qichang Zheng. Supplementary Sorafenib Therapies for Hepatocellular Carcinoma—A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology 2019; 53(7): 486 doi: 10.1097/MCG.0000000000001175
|
| 5 |
Jianzhen Lin, Liangcai Wu, Xue Bai, Yuan Xie, Anqiang Wang, Haohai Zhang, Xiaobo Yang, Xueshuai Wan, Xin Lu, Xinting Sang, Haitao Zhao. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016; 7(43): 71036 doi: 10.18632/oncotarget.11954
|
| 6 |
Giuseppe Cabibbo, Silvia Tremosini, Giovanni Galati, Giancarlo Mazza, Gennaro Gadaleta-Caldarola, Giuseppe Lombardi, Michela Antonucci, Rodolfo Sacco. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014; 14(7): 831 doi: 10.1586/14737140.2014.920694
|
| 7 |
Mingjun Bai, Tao Pan, Churen Zhou, Ming-an Li, Junwei Chen, Zhaolin Zeng, Duo Zhu, Chun Wu, Zaibo Jiang, Zhengran Li, Mingsheng Huang. Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results. Journal of Interventional Medicine 2019; 2(2): 69 doi: 10.1016/j.jimed.2019.09.005
|
| 8 |
Zhenzhen Zhang, Yanfang Wu, Tanghui Zheng, Xiaochun Chen, Guobin Chen, Hong Chen, Xinkun Guo, Susu Zheng, Xiaoying Xie, Boheng Zhang. Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Cancers 2022; 14(15): 3710 doi: 10.3390/cancers14153710
|
| 9 |
Jiaye Long, Baoxiang Chen, Zhaohui Liu. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1179431
|
| 10 |
Lei Liu, Hui Chen, Mengmeng Wang, Yan Zhao, Guohong Cai, Xingshun Qi, Guohong Han, Zhuoli Zhang. Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis. PLoS ONE 2014; 9(3): e91124 doi: 10.1371/journal.pone.0091124
|
| 11 |
Piao-Piao Jin, Shi-Yi Shao, Wang-Teng Wu, Xin-Yu Zhao, Bing-Feng Huang, Qi-Han Fu, Ri-Sheng Que, Qi-Da Hu. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Japanese Journal of Clinical Oncology 2018; 48(12): 1058 doi: 10.1093/jjco/hyy138
|
| 12 |
Aušra Bankauskaitė, Alvydas Česas, Algimatas Šimkaitis, Loreta Malinauskienė. Transarterial Chemoembolization With Doxorubicineluting Microspheres: Single-Center Review Of Safety Profile. Sveikatos mokslai 2016; 26(5): 48 doi: 10.5200/sm-hs.2016.071
|
| 13 |
Zhoujing Cheng, Lin He, Yingjie Guo, Yuhua Song, Shasha Song, Lijiu Zhang. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World Journal of Surgical Oncology 2020; 18(1) doi: 10.1186/s12957-020-02017-0
|
| 14 |
Hao Hu, Zhenhua Duan, Xiaoran Long, Yancu Hertzanu, Haibin Shi, Sheng Liu, Zhengqiang Yang, Gayle E. Woloschak. Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study. PLoS ONE 2014; 9(5): e96620 doi: 10.1371/journal.pone.0096620
|
| 15 |
Yeonjung Ha, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Yoon-Koo Kang, Kang Mo Kim. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget 2016; 7(45): 74303 doi: 10.18632/oncotarget.11030
|
| 16 |
Rong-Ce Zhao, Jing Zhou, Yong-Gang Wei, Fei Liu, Ke-Fei Chen, Qiu Li, Bo Li. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2017; 16(5): 493 doi: 10.1016/S1499-3872(17)60009-2
|
| 17 |
Guiliang Wang, Yan Liu, Shu-feng Zhou, Ping Qiu, Linfang Xu, Ping Wen, Jianbo Wen, Xianzhong Xiao. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatology International 2016; 10(3): 501 doi: 10.1007/s12072-015-9700-7
|
| 18 |
Dirk Graf, Daniel Vallböhmer, Wolfram Trudo Knoefel, Patric Kröpil, Gerald Antoch, Abdurrahaman Sagir, Dieter Häussinger. Multimodal treatment of hepatocellular carcinoma. European Journal of Internal Medicine 2014; 25(5): 430 doi: 10.1016/j.ejim.2014.03.001
|
| 19 |
Leida Zhang, Peng Hu, Xi Chen, Ping Bie, Lian-Yue Yang. Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis. PLoS ONE 2014; 9(6): e100305 doi: 10.1371/journal.pone.0100305
|
| 20 |
Lin Li, Wenzhuo Zhao, Mengmeng Wang, Jie Hu, Enxin Wang, Yan Zhao, Lei Liu. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0849-0
|
| 21 |
Jun Li, Wenhui Liu, Wenhua Zhu, Yinqiao Wu, Benyan Wu. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget 2017; 8(35): 59601 doi: 10.18632/oncotarget.19334
|
| 22 |
Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3545-5
|
| 23 |
Jyoti Narang-Master, Denise Rizzolo. Managing localized unresectable hepatocellular carcinoma. Journal of the American Academy of Physician Assistants 2015; 28(1): 27 doi: 10.1097/01.JAA.0000458854.46279.d8
|
| 24 |
Ciro Celsa, Giuseppe Cabibbo, Marco Enea, Salvatore Battaglia, Giacomo E. M. Rizzo, Anita Busacca, Paolo Giuffrida, Caterina Stornello, Giuseppe Brancatelli, Roberto Cannella, Salvatore Gruttadauria, Calogero Cammà. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. Liver International 2021; 41(5): 1105 doi: 10.1111/liv.14822
|
| 25 |
Yingqiang Zhang, Wenzhe Fan, Kangshun Zhu, Ligong Lu, Sirui Fu, Jinhua Huang, Yu Wang, Jianyong Yang, Yonghui Huang, Wang Yao, Jiaping Li. Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget 2015; 6(27): 24550 doi: 10.18632/oncotarget.4076
|
| 26 |
Jianghai Zhao, Hui Zhang, Lunshou Wei, Shuping Xie, Zhimin Suo. Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. Oncotarget 2017; 8(9): 15101 doi: 10.18632/oncotarget.13145
|